Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia 10Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Myelodysplastic Syndromes 7Multiple Myeloma 7Lymphoma, Non-Hodgkin 6Leukemia, Myeloid, Acute 5Hodgkin Disease 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Leukemia, Lymphocytic, Chronic, B-Cell 4Neoplasms, Plasma Cell 3Myeloproliferative Disorders 3Hematologic Neoplasms 3Recurrence 2Paraproteinemias 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoproliferative Disorders 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Congenital Abnormalities 2Burkitt Lymphoma 2Anemia, Aplastic 2Waldenstrom Macroglobulinemia 1Shwachman-Diamond Syndrome 1Sezary Syndrome 1Primary Immunodeficiency Diseases 1Preleukemia 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × Alemtuzumab × Clear all
NCT00983528 2020-08-12

Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia

University of California, San Diego

Phase 1/2 Terminated
6 enrolled 6 charts
LymphoidOther hematologic neoplasm

Leukemia, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡